Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Head and Neck Neoplasms × Digoxin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 1 Myelodysplastic Syndromes 1 Leukemia, Myeloid, Acute 1 Head and Neck Neoplasms 1 Colorectal Neoplasms 1

Interventions

pembrolizumab 22 Radiotherapy 17 Cisplatin 17 Cetuximab 11 Carboplatin 10 Nivolumab 8 Paclitaxel 7 durvalumab 6 Radiotherapy, Intensity-Modulated 5 Fluorouracil 5 Everolimus 4 Docetaxel 4 Cyclophosphamide 4 zalutumumab 3 spartalizumab 3 epacadostat 3 Ipilimumab 3 Immune Checkpoint Inhibitors 3 Gefitinib 3 Filgrastim 3 Celecoxib 3 Capecitabine 3 Amifostine 3 selpercatinib 2 fludarabine 2 cemiplimab 2 bintrafusp alfa protein, human 2 avelumab 2 Peripheral Blood Stem Cell Transplantation 2 Pemetrexed 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02906800 2017-10-19

DIGHANC

Assistance Publique - Hôpitaux de Paris

Phase 1/2 Unknown

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡